Stock-Based Compensation

6 Months Ended

Jun. 30, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

The Company classifies stock-based compensation expense in the accompanying Condensed Consolidated Statements of Operations and Comprehensive Loss, based on the department to which the recipient belongs. Stock-based compensation expense included in cost of goods sold and operating expenses during the six months ended June 30, 2018 and 2017, was as follows:



	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2018		2017		2018		2017
Cost of goods sold	$	267	$	304	$	503	$	473
Operating expenses:
Research and development	362		323		695		583
Clinical and regulatory affairs	256		160		432		420
Marketing and sales	706		1,283		1,820		2,341
General and administrative	2,674		1,164		3,836		2,371
Total operating expenses	$	3,998	$	2,930	$	6,783	$	5,715
Total	$	4,265	$	3,234	$	7,286	$	6,188